



# Biosimilar Patents Vs. Biologic Drugs: Challenges and Opportunities

Pranali P. Paradkar

Research Scholar, M. Pharmacy, Maharashtra, India

*(Received: 16 September 2018*

*Revised: 11 October 2018*

*Accepted: 11 November 2018)*

## KEYWORDS

biosimilars, biologics, patents, regulatory challenges, drug accessibility, innovation.

**ABSTRACT:** The growing expiration of patents on biologic drugs has catalyzed the entry of biosimilars, offering a significant opportunity to lower healthcare costs and improve patient access to critical therapies, especially in fields like oncology, rheumatology, and endocrinology. However, the transition is fraught with challenges that span legal, regulatory, technical, and market domains. This review explores the complex intersection between biosimilar patents and biologic drug development, focusing on how intellectual property frameworks and global regulatory environments shape market dynamics. Key barriers include patent thickets, litigation strategies, regulatory discrepancies, and skepticism from clinicians and patients about biosimilar efficacy and safety. While biosimilars hold the promise of saving billions in healthcare expenditure, their success depends on international harmonization of regulations, education of healthcare professionals, and policy reform to discourage evergreening. The paper concludes that a balanced ecosystem—where innovation is protected but not monopolized—is essential to unlock the full potential of biosimilars in promoting equitable and sustainable healthcare globally.

## 1. INTRODUCTION

Biologic drugs have revolutionized modern medicine, especially in oncology, rheumatology, and rare diseases. Their complex structures and production methods, however, mean that they come with high price tags, contributing significantly to global healthcare costs. As patents for several blockbuster biologics expire, biosimilars—drugs highly similar to approved biologics—offer a pathway to reduce costs and expand patient access. Despite these advantages, biosimilars face multifaceted challenges due to stringent patent protections, regulatory barriers, and market competition. This article analyzes these dynamics, highlighting both the obstacles and opportunities within the biosimilar landscape.

## 2. LITERATURE REVIEW

The literature indicates that the development and approval of biosimilars are far more complex than traditional generics due to their biological nature. Regulatory agencies like the FDA and EMA have

developed unique pathways emphasizing comparability exercises. However, patent thickets and litigation, as observed with Herceptin and Humira, delay biosimilar entry. Authors like McCamish and Woollett (2011), and Dörner et al. (2013) underscore the necessity for streamlined pathways and global harmonization. Emerging markets such as India have also introduced specific biosimilar guidelines, reflecting growing global interest but varied implementation strategies.

## 3. DISCUSSION

Patent challenges present a double-edged sword: while they protect innovation, they can also be used strategically to block biosimilar competition. Techniques such as 'evergreening' and 'patent clustering' are widely criticized. The regulatory complexities surrounding biosimilar approval further complicate market access. Meanwhile, biosimilars promise substantial healthcare savings—as much as \$44 billion in the U.S. alone between 2014 and 2024. Clinicians, especially in rheumatology and oncology, are gradually accepting



biosimilars, though concerns about immunogenicity, interchangeability, and extrapolation persist. Education, stakeholder engagement, and stronger pharmacovigilance systems are essential to increasing uptake.

#### 4. CONCLUSION

The intersection of biosimilar patents and biologic drug development is fraught with legal, technical, and ethical challenges. Yet, the potential benefits in cost reduction and increased accessibility cannot be ignored. Policymakers must strike a balance between incentivizing innovation and preventing monopolistic practices. International regulatory harmonization, judicial reform around patent practices, and enhanced stakeholder education are pivotal to realizing the full promise of biosimilars.

#### 5. REFERENCES

1. Ghosh P.K., Similar Biologics: Global Opportunities and Issues, *J Pharm Pharm Sci*, 2016, 19(4) 552 – 596.
2. Blackstone E.A., Fuhr J.P., The Economics of Biosimilars, *Am Health Drug Benefits*, 2013, 6(8), 469-478.
3. Rotenstein L.S., Ran N., Shivers J.P., Yarchoan M., Close K.L., Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?, 2012, 30(4), 138-150.
4. Sekhon B.S., Saluja V., Biosimilars: an overview, *Biosimilars*, 2011, 1-11.
5. Moorkens E., Jonker-Exler C., Huys I., Declerck P., Simoens S., Vulto A., Overcoming barriers to the market access of Biosimilars in the European Union: the case of Biosimilar Monoclonal Antibodies, *Frontiers in Pharmacology*, Jun 2016, 7.
6. Roger S.D., Mikhail A., Biosimilars: Opportunity or Cause for Concern?, *J Pharm Pharmaceut Sci*, 2007, 10(3), 405-410.
7. Paradise J., Follow-On Biologics: Implementation Challenges and Opportunities, 2011, 501-510.
8. Johnson J.A., Biologics and Biosimilars: Background and Key Issues, Congressional Research Service, Oct 2017.
9. Tsuruta L.R., Santos M.L., Biosimilars Advancements: Moving on to the Future, *Biotechnol. Prog.*, 2015, 31(5), 1139-1149.
10. McCamish M., Woollett G., The State of the Art in the Development of Biosimilars, *Clinical pharmacology & Therapeutics*, Mar 2012, 91(3), 405-417.
11. Andrews L., Ralston S., Blomme E., Barnhart K., A snapshot of biologic drug development: Challenges and opportunities, *Human and Experimental Toxicology*, 2015, 34(12), 1279–1285.
12. McCamish M., Woollett G., Worldwide experience with biosimilar development, *Landes Bioscience*, 2011, 209-217.
13. Gough S., Biosimilar insulins: opportunities and challenges, *Practical diabetes*, 2013, 30(4), 146-147a.
14. Ghia C., Shah D., Rambhad G., Mubashir A., Upadhyay S., Biologics, biosimilars, intended copies and the era of competitive medicine, *apollo medicine*, 2015, 103-111.
15. Rushvi P., Charmy K., Nirav C., Narendra C., Biosimilars: an Emerging Market Opportunities in India, *Pharmaceutical Regulatory Affairs: Open Access*, 2016, 5(1), 1-7.
16. Mulcahy A.W., Predmore Z., Mattke S., The Cost Savings Potential of Biosimilar Drugs in the United States, *Rand corporation*, 2014.
17. Farhat F., Othman A., Karak F., Kattan J., Review and results of a survey about biosimilars prescription and challenges in the Middle East and North Africa region, *SpringerPlus*, 2016, 1-9.
18. Bocquet F., Paubel P., First monoclonal antibody biosimilars: tackling the challenge of substitution, *Journal of Medical Economics*, 2016, 645–647.
19. Ahmed I., Kasper B., Sharma U., Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States, *Clinical Therapeutics*, 2012, 34(2), 400-419.
20. Mysler E., Pineda C., Horiuchi T., Singh E., Mahgoub E., Coindreau J., Jacobs I., Clinical and regulatory perspectives on biosimilar



- therapies and intended copies of biologics in rheumatology, *Rheumatol Int*, 2016, 613–625.
21. Hou J.J., Codamo J., Pilbrough W., Hughes B., Gray P.P., Munro T.P., New frontiers in cell line development: challenges for biosimilars, *J Chem Technol Biotechnol*, 2011, 895–904.
  22. Bourgoin A.F., Nuskey B., An outlook on us biosimilar competition, Thomson Reuters, April 2013, 1-16.
  23. Nelson K.M., Gallagher P.C., Biosimilars lining up to compete with Herceptin – opportunity knocks, *Expert Opinion on Therapeutic Patents*, 2014, 24(11), 1149-1153.
  24. Dörner T., Strand V., Castañeda-Hernández G., Ferraccioli G., Isaacs J.D., Kvien T.K., Martin-Mola E., Mittendorf T., Smolen J.S., Burmester G.R., The role of biosimilars in the treatment of rheumatic diseases, *Ann Rheum Dis*, 2013, 322–328.
  25. Roger S.D., Biosimilars: How similar or dissimilar are they?, *NEPHROLOGY*, 2006, 341–346.